• Publications
  • Influence
Thalidomide: dermatological indications, mechanisms of action and side‐effects
Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects. However, it has since made a remarkableExpand
  • 173
  • 11
  • PDF
Failure of omalizumab for treatment of severe adult atopic dermatitis.
Atopic dermatitis has been associated with elevated levels of IgE. Omalizumab is a monoclonal anti-IgE antibody currently approved for the treatment of asthma. We report the failure of omalizumab toExpand
  • 152
  • 9
Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation.
BACKGROUND Treating psoriasis in pregnant and lactating women presents a special challenge. For ethical reasons, prospective randomized control trials have not been conducted in this patientExpand
  • 81
  • 8
Autoimmune bullous dermatoses: a review.
Bullous dermatoses can be debilitating and possibly fatal. A selection of autoimmune blistering diseases, including pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid, cicatricialExpand
  • 114
  • 8
  • PDF
Consensus guidelines for the management of plaque psoriasis.
The Canadian Guidelines for the Management of Plaque Psoriasis were reviewed by the entire National Psoriasis Foundation Medical Board and updated to include newly approved agents such as ustekinumabExpand
  • 141
  • 7
From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
BACKGROUND Many studies have identified cardiovascular risk factors in patients with psoriasis. Some psoriasis therapies may increase cardiovascular disease (CVD) and others may decrease CVD. Expand
  • 106
  • 6
  • PDF
Clinical manifestations of varicella-zoster virus infection.
Infections by VZV, the virus that causes chickenpox and herpes zoster, usually are diagnosed by the classic clinical presentations. In immunocompromised patients, however, the atypical presentationExpand
  • 35
  • 4
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.
BACKGROUND Biologics are widely used in the treatment of psoriasis and psoriatic arthritis. OBJECTIVE Our aim was to arrive at a consensus on the kind of monitoring and the vaccinations that shouldExpand
  • 112
  • 3
Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation.
BACKGROUND Patients with psoriasis and HIV infection often present with more severe and treatment-refractory cutaneous disease. In addition, many of these patients have significant psoriaticExpand
  • 103
  • 3
From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other
BACKGROUND No consensus exists regarding the optimal laboratory screening for hepatitis B infection that should be performed before initiating therapy with tumor necrosis factor-alfa inhibitors orExpand
  • 54
  • 3